A Randomized Phase III Study of Oxaliplatin (Eloxatin) and Capecitabine on Top of Sorafenib Versus Sorafenib Alone as First-line Palliative Treatment in Advanced Hepatocellular Carcinoma Patients
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2011
At a glance
- Drugs Capecitabine; Oxaliplatin; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- 21 Oct 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 21 Oct 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Dec 2010 New trial record